189
Results-
Press ReleaseFernando Junoy appointed Pierre Fabre Laboratories’ International Managing DirectorCreated on : - Last modified on :Castres, October 31, 2024 – Pierre Fabre Laboratories announces the appointment of Fernando Junoy as International Managing Director. In this capacity, he reports to Eric Ducournau, Chief Executive Officer, and joins the Executive Committee. Fernando Junoy’s mission will be to boost the international growth for the company. Pierre Fabre Laboratories generates 70% of its revenue internationally and aims to increase this share to 80% by 2030, while consolidating its profitability and cash flow.
-
Press ReleasePierre Fabre receives European approval for BRAFTOVI® (encorafenib)Created on : - Last modified on :Pierre Fabre receives European approval for BRAFTOVI® (encorafenib) in combination with cetuximab for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer
-
Press ReleaseChinese beauty company Yatsen acquires iconic skincare brand GALENIC from French group Pierre FabreCreated on : - Last modified on :Guangzhou (China), Castres (France); October 30, 2020 - Chinese beauty company Yatsen has acquired GALENIC, an iconic skincare brand, after reaching an acquisition agreement with French pharmaceutical and dermo-cosmetic group Pierre Fabre. The take-over will be effective on November 1st, 2020. Pierre Fabre will own a minority stake of 10% in the affiliate created by Yatsen to host Galénic assets in Europe.
-
Press ReleaseCreation of a research partnership between Pierre Fabre and Y-Biologics for the development of new immunotherapies based on monoclonal antibodiesCreated on : - Last modified on :Daejeon (South Korea), Castres (France), November 20th, 2020 – The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have announced their plans to form a strategic partnership in the field of immuno-oncology research. The decision has been acknowledged through a letter of intent signed by both parties and will be confirmed in the coming months through a detailed agreement. The collaboration is set to run for three years, with the possibility of a two-year extension.
-
Press ReleaseTRIASORB™: the launch of a new ultra broad-spectrum sun filter, proven to be safe for human use and eco-friendly for marine biodiversityCreated on : - Last modified on :
-
Press ReleaseSouth-Korean biotech Y-Biologics and French mid-pharma Pierre Fabre enter into a worldwide exclusive license agreement in the highly innovative field of immuno-oncologyCreated on : - Last modified on :Daejeon (South Korea), Castres (France), July 6th, 2021 – The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have entered into a license agreement granting worldwide exclusive rights to Pierre Fabre to develop and commercialize a family of human antibodies generated through the phage display human antibody Ymax®-ABL library owned by Y-Biologics.
-
Press ReleasePuma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater ChinaCreated on : - Last modified on :Puma Biotechnology and CANbridge Pharmaceuticals Terminate License Agreement in Greater China
-
Press ReleaseWorldwide premiere : Pierre Fabre launches the Green Impact IndexCreated on : - Last modified on :The first rating tool which, through grades of A, B, C, or D, can be used to measure, improve and communicate information on the environmental and societal impact of cosmetics and family health products, based on a methodology which has been validated and endorsed by AFNOR certification.
-
Press ReleaseAtara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (tab-cel®)Created on : - Last modified on :Pierre Fabre to Commercialize Tab-cel® for Epstein-Barr Virus (EBV)-Positive Cancers in Europe, Middle East, Africa, and Other Select Emerging Markets Atara to Receive Upfront Payment of USD 45 Million, and Up to Approximately USD 320 Million in Total Milestones, Plus Significant Double-digit Tiered Royalties as a Percentage of Net Sales Atara Retains Full Commercialization Rights to Tab-cel® in the United States and Other Major Markets
-
Press ReleasePierre Fabre and the EspeRare Foundation start the EDELIFE clinical trial of a prenatal treatment for a rare genetic disease, XLHEDCreated on : - Last modified on :Geneva, Switzerland, Castres, France (November 15, 2021) – The EspeRare Foundation and the Pierre Fabre group announced today the start of the EDELIFE clinical trial aimed at confirming the safety and efficacy of ER004, a prenatal treatment for XLHED (X-linked Hypohidrotic Ectodermal Dysplasia), a rare and debilitating congenital disease. If positive, the study could lead to the first approved treatment for XLHED by 2026.
We take care of life by designing and developing innovative solutions inspired by consumers and patients, and contributing to the well-being of everyone from health to beauty.